Dataset from Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study

This extension study is designed to assess the safety of GSK Biological's human papillomavirus (HPV) vaccine GSK580299 in female subjects who took part in the primary study NCT00294047 and received the control vaccine in countries for which the licensed GSK HPV vaccine is not indicated for the subject's age group (26 years and older). This study is thus conducted to enable all women who received the control placebo in the primary NCT00294047 study to receive the GSK580299 vaccine.

本扩展研究旨在评估葛兰素史克生物（GSK Biological）的人乳头瘤病毒（HPV）疫苗GSK580299在参与过初始研究NCT00294047、且在获批葛兰素史克HPV疫苗不适用于其年龄组（26岁及以上）的国家中接种了对照疫苗的女性受试者中的安全性。本研究的开展旨在使所有在初始研究NCT00294047中接受对照安慰剂的女性能够接种GSK580299疫苗。